Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukemia: A systematic review and meta-analysis

Researchers performed a literature review to evaluate the efficacy and safety of CAR T-cell therapy for patients with relapse/refractory B-cell acute lymphoblastic leukemia. Anti-CD22 therapies had the highest minimal residual disease negative complete remission rates and lowest relapse rates. Combination CAR T-cell therapy and haploidentical stem cell transplantation also showed improved relapse rates. From a safety perspective, bispecific anti-CD19/22 therapies had the lowest rates of cytokine release syndrome, and anti-CD22 therapies had the lowest rates of immune effector cell-associated neurotoxicity syndrome. Adding CD28ζ to anti-CD19 CAR T-cell therapy showed superior efficacy in terms of reduced relapse rates and favorable safety profiles.